Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06641713
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-12
Brief Title:
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Hepatic Arterial Infusion Chemotherapy Compared With Transcatheter Arterial Chemoembolizationin Intermediate-advanced Huge Hepatocellular Carcinoma a Multicenter Retrospective Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to compare the efficacy of transcatheter arterial chemical embolization TACE with hepatic arterial infusion chemotherapy HAIC for patients with intermediate-advanced huge hepatocellular carcinoma
Detailed Description:
Transcatheter arterial chemoembolization TACE and hepatic arterial infusion chemotherapy HAIC are effective and safe for hepatocellular carcinoma HCC For huge HCC 10 cm the prognosis of this high tumor-burden subtype usually indicates poor outcome and big challenge TACE is difficult to completely embolize all tumor arteries so patients have limited benefit from pure hepatic artery embolization At the same time excessive embolization will lead to massive tumor necrosis in a short time and inflammatory necrosis factor will enter the blood resulting in systemic inflammatory response HAIC have showed good efficacy especially for advanced huge HCC 10 cm complicated with portal vein tumor thrombus and arteriovenous fistula and HAIC therapy can be performed with better and higher tumor control
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None